Previous studies have demonstrated that patients with HCC expressing CK19 (i.e., CK19(+) HCC) have a more severe tumor invasion, a higher rate of lymph node metastasis, earlier recurrence, and worse survival rate compared to those with CK19(-) HCC [10, 11]. This evidence concerns the gene KRT19 and neoplasm.